Taiwan-based clinical stage biotechnology company Formosa Pharmaceuticals (TWO:6838) announced on Thursday that it has signed a licensing deal with Medvisis Switzerland AG for clobetasol propionate ophthalmic suspension (APP13007) in Switzerland and Liechtenstein.
APP13007 treats post-surgical eye inflammation and pain.
Under the agreement Medvisis will exclusively commercialise the drug in Switzerland and Liechtenstein. The deal includes upfront payment, sales milestones and additional consideration.
Approved by the US Food and Drug Administration (FDA) in March 2024, APP13007 was launched in the United States in September.
APP13007 uses Formosa's APNT nanoparticle platform, enabling a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. Surgeon surveys highlighted rapid pain relief and low side effects as key advantages.
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz